In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Compass Therapeutics Inc (NASDAQ: CMPX) closed the day trading at $3.39 down -7.88% from the previous closing price of $3.68. In other words, the price has decreased by -$7.88 from its previous closing price. On the day, 6.71 million shares were traded. CMPX stock price reached its highest trading level at $3.81 during the session, while it also had its lowest trading level at $3.38.
Ratios:
For a better understanding of CMPX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.66 and its Current Ratio is at 7.66. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On April 02, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $6.
On February 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $12.Guggenheim initiated its Buy rating on February 24, 2025, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 27 ’25 when Schuetz Thomas J. bought 10,000 shares for $2.11 per share. The transaction valued at 21,100 led to the insider holds 6,480,825 shares of the business.
GORDON CARL L sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 3,571,428 shares for $1.59 each. As a result, the insider received 5,678,571 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 581630784 and an Enterprise Value of 377732672.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.29, which has changed by 1.1320755 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $4.08, while it has fallen to a 52-week low of $1.27. The 50-Day Moving Average of the stock is 7.02%, while the 200-Day Moving Average is calculated to be 36.47%.
Shares Statistics:
Over the past 3-months, CMPX traded about 1.13M shares per day on average, while over the past 10 days, CMPX traded about 1586130 shares per day. A total of 138.28M shares are outstanding, with a floating share count of 109.99M. Insiders hold about 35.89% of the company’s shares, while institutions hold 43.14% stake in the company. Shares short for CMPX as of 1756425600 were 10251661 with a Short Ratio of 9.07, compared to 1753920000 on 8108960. Therefore, it implies a Short% of Shares Outstanding of 10251661 and a Short% of Float of 9.6499994.
Earnings Estimates
The dynamic stock of Compass Therapeutics Inc (CMPX) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.04 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.4 and -$0.6 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.56, with 7.0 analysts recommending between -$0.25 and -$0.76.
